Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025

Rhea-AI Summary

Karyopharm (Nasdaq: KPTI) will report third quarter 2025 financial results on Monday, November 3, 2025. Management will host a conference call and live audio webcast at 8:00 a.m. ET the same day to discuss results and company updates.

Investors may join by phone at (800) 836-8184 (U.S.) or (646) 357-8785 (international) and should dial at least 10 minutes early. A live webcast and accompanying slides will be available under Events & Presentations on the company's Investor website, with an archived webcast posted about two hours after the event.

-- Conference Call Scheduled for Monday, November 3, 2025, at 8:00 a.m. ET --

NEWTON, Mass., Oct. 27, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report third quarter 2025 financial results on Monday, November 3, 2025. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Monday, November 3, 2025, to discuss the financial results and other company updates.

To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. An archived webcast will be available on the Company's website approximately two hours after the event.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO^® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in 50 ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO^®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-report-third-quarter-2025-financial-results-on-november-3-2025-302594177.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

When will Karyopharm (KPTI) report Q3 2025 results?

Karyopharm will report Q3 2025 results on Monday, November 3, 2025.

What time is the Karyopharm (KPTI) Q3 2025 conference call?

The conference call and live webcast begin at 8:00 a.m. ET on November 3, 2025.

How can investors access the Karyopharm (KPTI) Q3 2025 call by phone?

Dial (800) 836-8184 (U.S.) or (646) 357-8785 (international) and join at least 10 minutes before the start time.

Where will the Karyopharm (KPTI) live webcast and slides be posted?

The live webcast and slides will be available under Events & Presentations in the Investor section at http://investors.karyopharm.com/events-presentations.

When will the archived webcast for Karyopharm (KPTI) Q3 2025 be available?

An archived webcast will be posted on the company's website approximately two hours after the event.